CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-05-24
DOI
10.3389/fimmu.2019.01149
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor Antigen Escape from CAR T-cell Therapy
- (2018) Robbie G. Majzner et al. Cancer Discovery
- Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells
- (2017) Lynsey M. Whilding et al. MOLECULAR THERAPY
- CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy
- (2017) Nan Chen et al. OncoImmunology
- Chimeric antigen receptors: driving immunology towards synthetic biology
- (2016) Michel Sadelain CURRENT OPINION IN IMMUNOLOGY
- Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety
- (2016) Avery D. Posey et al. IMMUNITY
- Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
- (2016) Avery D. Posey et al. IMMUNITY
- Driving CAR T-cells forward
- (2016) Hollie J. Jackson et al. Nature Reviews Clinical Oncology
- A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis
- (2016) R Zhou et al. ONCOGENE
- Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment
- (2016) Ainhoa Arina et al. SEMINARS IN IMMUNOLOGY
- Antibody-Guided In Vivo Imaging for Early Detection of Mammary Gland Tumors
- (2016) Laura Jeffords Moore et al. Translational Oncology
- The interplay of effector and regulatory T cells in cancer
- (2015) Rahul Roychoudhuri et al. CURRENT OPINION IN IMMUNOLOGY
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis
- (2015) Xiao-wei Qi et al. Scientific Reports
- Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor
- (2014) S. Wilkie et al. JOURNAL OF IMMUNOLOGY
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
- (2014) P. S. Adusumilli et al. Science Translational Medicine
- The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer
- (2013) Jennifer M. Curry et al. JOURNAL OF SURGICAL ONCOLOGY
- The Basic Principles of Chimeric Antigen Receptor Design
- (2013) Michel Sadelain et al. Cancer Discovery
- Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
- (2012) Scott Wilkie et al. JOURNAL OF CLINICAL IMMUNOLOGY
- MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches
- (2012) D W Kufe ONCOGENE
- PD-1 and BTLA and CD8+T-cell “exhaustion” in cancer
- (2012) Cara Haymaker et al. OncoImmunology
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More